$ALAB

Dyckerhoff Stefan A sold $1.1M of ALAB

Dyckerhoff Stefan A sold 3,505 shares of Astera Labs, Inc. (ALAB) at an average of $311.83 ($309.29–$313.07, $1.09M total) across 3 trades on 2026-08-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Dyckerhoff Stefan A
Published Aug 10, 2026, 8:17 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 10, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ALAB
Neutral
medium confidence
Mentioned
$ALAB
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALABNeutralLow
01

Why it matters

The only new information is the director’s sale size, price range, and remaining holdings after the transaction; it does not include any accompanying corporate or business update.

02

Market read

Traders may note the insider sale for sentiment, but the 10b5-1 structure makes it a low-signal catalyst.

03

What to watch

The filing does not disclose any new company fundamentals, guidance, or operational changes; it only provides transaction details and post-sale holdings.

Relevance 5/10Novelty 3/10Timing: Filed 2026-08-10 after the 2026-08-06 sale trades were executed.

Background

The article is an SEC Form 4 insider transaction disclosure for Astera Labs, Inc. (ALAB).

Company-level read

Ticker impact

$ALABNeutralMedium confidence
Context

Astera Labs director Stefan Dyckerhoff sold 3,505 shares in open-market trades for about $1.09M under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this filing; any impact is likely short-lived.

Evidence & confidence

The transaction is an open-market sale by a director and explicitly tied to a pre-arranged 10b5-1 plan, which typically reduces interpretive value versus discretionary selling.

Market effects

No clear sector read-through from a single director 10b5-1 sale.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • Astera Labs, Inc.

    US-listed company whose director insider sale is disclosed on Form 4.

  • Dyckerhoff Stefan A

    Director who executed open-market sales under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALABMed

ALAB Benefits From PCIe Demand: Can It Stay Ahead of Its Competitors?

Astera Labs (ALAB) reported record Q2 2026 revenue of $392.4M, up 104% year over year, with PCIe 6 products at over 50% of revenue. The company said Scorpio X-Series will be its largest product family by Q3 2026. It expects Q3 revenue of $540M-$560M. The article also cites competition from Marvell (MRVL) and Credo (CRDO).

$ALABMedAI 8/10

Astera Labs (ALAB) Q2 2026 Earnings Call Transcript

Astera Labs (NASDAQ:ALAB) reported Q2 2026 revenue of $392.4M, up 27% sequentially and 104% year over year, with non-GAAP gross margin of 73.7% and non-GAAP diluted EPS of $0.80. Q3 guidance calls for revenue of $540M to $560M and EPS of $1.16 to $1.21, driven by the Scorpio X-Series ramp and PCIe 6.0 adoption.

$ALABHighAI 9/10

Alamar Biosciences Shares Rise 18% After Second-Quarter Revenue Jumps 82% Year-Over-Year

Alamar Biosciences shares rose about 18% after the company reported Q2 2026 revenue of $29.4 million, up 82% year over year, and provided first full-year 2026 revenue guidance of $116 million to $120 million. The stock closed at $32.91. Alamar also launched new NULISAseq panels and set targets to exceed 100 instrument systems and $400,000+ annual pull-through per instrument.

$ALABMed

Astera Labs Beat And Guided Higher, Then Fell Because The Rally Came First

Astera Labs (ALAB) reported record fiscal Q2 2026 results, with revenue of $392.4M up 104% year over year, and issued fiscal Q3 2026 guidance of $540M to $560M, above expectations. The stock later fell about 12% after four prior up sessions. The article attributes the shift to product mix, with PCIe 6 and Scorpio switch family ramping, and a non-GAAP gross margin guide down to about 72% from 74%.